Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib safety, tolerability and antiretroviral activity in recent HIV-1 infection
2024-519641-30-00Phase 2Authorised
- Sponsor
- IDIBAPS
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Dasatinib with Placebo (2 arms). Primary endpoint: Primary safety and tolerability endpoint. Planned start Dec 2024; status: authorised.
02
Drugs
dasatinib
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2024-519641-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519641-30-00.